Pipelines Report 2024: M&A and AI momentum
Merger and acquisition activity is on the rise after the biopharma industry moved on from the COVID-19 pandemic, while the role of AI in drug development is reaching new levels.
This author has not written his bio yet.
But we are proud to say that Andrew Humphreys contributed 3897 entries already.
Merger and acquisition activity is on the rise after the biopharma industry moved on from the COVID-19 pandemic, while the role of AI in drug development is reaching new levels.
MedAdNews talked to Jane Reed, director of life sciences with Linguamatics, an IQVIA company, about how pharma companies are using new AI-based technologies to advance their safety processes and other topics.
2024 will be the year that AI integration will be pivotal to the continued success of those working throughout biotech and life sciences, especially for those involved in the drug discovery and regulation processes.
As the public’s interest in COVID-19 products continues to wane and the autoimmune medicine Humira settles into life without exclusivity, the anti-cancer agent Keytruda is set to rule the drug marketplace for years to come.
Blockbuster deals are on the rise as drug manufacturers navigate through patent cliffs, pricing pressures, and evolving regulations while M&A activity remains an integral part of the strategic landscape.
A Q&A with Alister Campbell, VP, global head of science and technology at Dotmatics.
Dealing with the seismic effects of the COVID-19 pandemic, the biopharma industry continues to break new ground during a transformative era of product innovation.
Med Ad News talked to Jane Myles, vice president of clinical trial innovation at Curebase, about improving clinical trials and patient experience.
Med Ad News talked to Ittai Dayan, M.D., co-founder and CEO of Rhino Health, about federated learning in clinical trials.
This paper explains the challenges patients face in traditional trial settings as well as how Aparito overcomes these challenges; how remote video is able to capture real-world evidence (RWE) while improving the patient experience; and how Aparito provides more meaningful patient data while protecting patient privacy.